What This Study Looked At
After a major ST-elevation myocardial infarction (STEMI) — the most serious form of heart attack — patients are treated with primary percutaneous coronary intervention (PCI), the emergency stenting procedure that restores blood flow to the heart. Recovery in the weeks and months afterward depends heavily on how the heart muscle remodels: ideally returning toward its normal shape and function, rather than enlarging and weakening (a process called adverse left ventricular remodelling). In 2017 a Japanese research team led by Yoshinori Katsumata at Keio University School of Medicine published the first-in-human pilot study testing whether adding hydrogen gas inhalation during the acute PCI procedure could support that recovery.
The study, published in the Circulation Journal, was a prospective, open-label, rater-blind clinical trial in 20 STEMI patients. Patients were assigned to one of two groups: the hydrogen-inhalation group received a mixture of 1.3 percent hydrogen and 26 percent oxygen during PCI, while the control group received 26 percent oxygen alone. The primary endpoints centred on safety, feasibility, and a panel of cardiac magnetic resonance imaging (CMR) outcomes including the cardiac salvage index at day 7 and left-ventricular remodelling at 6 months.
What They Found
The most important finding from a first-in-human study is safety, and the trial established that clearly: there were no serious adverse events related to hydrogen gas inhalation in any patient. Delivering hydrogen at this concentration during an acute cardiac intervention is feasible and safe.
At 7 days, the cardiac salvage index measured by CMR did not differ significantly between the two groups — a finding the authors anticipated, since the study was small and not powered to detect early outcome differences. The more interesting signal came later: at 6 months, the CMR follow-up suggested that hydrogen inhalation may have promoted left-ventricular reverse remodelling, the direction of recovery clinicians want to see after a major MI.
What This Means in Context
This is explicitly a pilot study — small, exploratory, and designed primarily to test whether the intervention could be delivered safely in the acute cardiac setting. On that primary question the answer was clear: yes. The 6-month remodelling observation is the kind of exploratory signal that justifies the next, larger trial — not the kind of result that establishes clinical efficacy on its own.
The biological rationale aligns with the broader hydrogen literature. Reperfusion injury — the burst of oxidative damage that follows the sudden restoration of blood flow after a heart attack — is one of the most well-characterised forms of oxidative stress in clinical medicine, and the kind of injury hydrogen has been shown to attenuate in preclinical work. The authors concluded that hydrogen inhalation during PCI is feasible and safe, and may also promote left-ventricular reverse remodelling at 6 months, warranting a larger trial.
What It Means for You
Hydrogen inhalation in the acute cardiac setting is a clinical intervention delivered by hospital teams, not a self-administered approach. This study matters less as a guide to what individuals should do and more as part of the gradually accumulating evidence that hydrogen is being taken seriously in serious clinical settings — and is generating safety data that supports broader use in less acute contexts. If you have cardiovascular risk factors or have experienced a cardiac event, talk to your treating cardiologist before considering any complementary approach.
Citation: Katsumata, Y., Sano, F., Abe, T., Tamura, T., Fujisawa, T., Shiraishi, Y., Kohsaka, S., Ueda, I., Homma, K., Suzuki, M., Okuda, S., Maekawa, Y., Kobayashi, E., Hori, S., Sasaki, J., Fukuda, K., & Sano, M. (2017). The Effects of Hydrogen Gas Inhalation on Adverse Left Ventricular Remodeling After Percutaneous Coronary Intervention for ST-Elevated Myocardial Infarction — First Pilot Study in Humans. Circulation Journal, 81(7), 940–947. PubMed
